Breaks Categories: News

FridayMar 05, 2021 9:57 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) to Participate in Upcoming Stephens Best Ideas Conference

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics (“DTx”) market, has been selected to participate in the virtual Stephens 2021 Best Ideas Conference. The conference is slated for March 11, 2021. As part of that participation, Dario CEO Erez Raphael and president/general manager Rick Anderson will presenting. Their presentation is scheduled to begin at 9 a.m. ET on March 11; a replay of their presentation will be available following the conference. DarioHealth is committed to change how people with chronic conditions manage their health. The company has one of the highest-rated diabetes and hypertension solutions on the market and is focused…

Continue Reading

ThursdayMar 04, 2021 1:12 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Upcoming H.C. Wainwright Global Life Sciences Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the company’s CEO, John Climaco, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. According to the update, CNSP management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the event. Interested parties should visit https://ibn.fm/XlGLZ for more information and to register for the conference. To view the full press release,…

Continue Reading

ThursdayMar 04, 2021 11:29 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Unveils New Website, Completion of Corporate Rebranding Strategy

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announced that it has completed its corporate rebranding efforts. Those efforts included the launch of a completely redesigned website. XPhyto chose to rebrand itself as part of its commitment to operational achievement in 2021, which included a number of product-development programs advancing from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto is targeting focused investment in impact-driven innovation as well as value creation through commercialization of its development…

Continue Reading

WednesdayMar 03, 2021 10:36 am

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Isolates and Concentrates a Mustard-Derived Molecule that Acts as a Systemic, Non-Selective Bioherbicide

MustGrow (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced that it has isolated and concentrated an additional molecule, thiocyanate, from mustard seed. According to the update, thiocyanate is responsible for the systemic activity behind the mustard plant's natural herbicidal (weed-killer) properties and is the third molecule from mustard seed that MustGrow has isolated, extracted and concentrated. MustGrow had previously announced herbicidal proof-of-concept success without isolating thiocyanate and now expects to build on those studies with identification of this additional herbicidal mode-of-action. MustGrow has commenced greenhouse testing…

Continue Reading

TuesdayMar 02, 2021 1:44 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes $10.2M Private Placement

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has closed its previously announced private placement to institutional and accredited investors. According to the update, the company sold 1,321,132 shares of its common stock at a purchase price of $7.75 per share for $10.2 million in the private placement. Processa Pharmaceuticals secured net proceeds of $9.9 million, which will enable the company to be funded through 2023 and either expand the clinical development of PCS6422 or conduct enabling toxicology studies to advance PCS11T. “We…

Continue Reading

TuesdayMar 02, 2021 1:00 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Releases Results of New Clinical Study Showing Value of Personalization

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced the results of a new clinical study that examined the connection between personalization and sustained behavior change in digital health. The study indicates increased digital engagement resulted in 43% improvement in blood glucose levels. The study results were compiled in a paper titled "Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study," which was published in the “Journal of Medical Internet Research (JMIR) Diabetes.” The study evaluated data from 998 people with Type 2 diabetes who used DarioHealth's digital health platform. The study focused…

Continue Reading

TuesdayMar 02, 2021 11:25 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Secures $3.6M from Exercised Warrants

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced its receipt of approximately CA$3.6M (US$2.9M) in warrant exercises since the start of 2021. “Achieving our first commercial sales in combination with a very positive outlook for 2021 has resulted in the appreciation of our share price over the last few months,” said Dr. Jack Regan, LexaGene’s CEO and founder. “The receipt of exercised warrants has significantly added to our treasury and puts us in a strong financial position for 2021.” To view the full press release, visit https://ibn.fm/tqFbl About…

Continue Reading

TuesdayMar 02, 2021 10:47 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in ‘Fireside Chat’ at Upcoming H.C. Wainwright Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its chairman and CEO, James Sapirstein, will participate in a “fireside chat” with Yi Chen, managing director, Equity Research at H.C. Wainwright, during the H.C. Wainwright Global Life Sciences Conference being held virtually March 9-11, 2021. Sapirstein will provide an overview of AzurRx’ business and clinical development programs and discuss anticipated 2021 milestones during the fireside chat scheduled to take place at 7:00 a.m. ET on Tuesday, March 9. Additionally, Sapirstein and members of the AzurRx management team will be…

Continue Reading

TuesdayMar 02, 2021 10:21 am

BioMedNewsBreaks – PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) Announces Record Third Quarter Revenue, Other Q3 Highlights

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, has released its interim unaudited financial results for the three and nine months ended December 31, 2020. A highlight of the report is the company’s record revenue of C$1,832,484 for the three months ended December 31, 2020 — an increase of 298% over gross revenue of C$459,982 reported in Q2. The report also noted that PlantX saw a gross margin of 20% for the same period, an increase from 5.7% in Q2. In addition, cost of sales for the company over the same period totaled C$1,465,879. The announcement noted…

Continue Reading

MondayMar 01, 2021 1:19 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for March Investor Conferences

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its plans to participate in two virtual investor conferences in the month of March. These include the Sachs 14th Annual European Life Sciences CEO Forum taking place March 10-12, as well as the 33rd Annual Roth Conference scheduled to be held from March 15-17, 2021. The company’s president and CEO, Rodney Varner, will lead Genprex’s presentations and will be available for one-on-one meetings with investors throughout the conferences. Interested parties should visit https://ibn.fm/MUouk and https://ibn.fm/J1qLh to register. The presentations will…

Continue Reading